Cyclo Therapeutics Stock (NASDAQ:CYTH)
Previous Close
$0.69
52W Range
$0.59 - $2.12
50D Avg
$0.72
200D Avg
$1.18
Market Cap
$20.71M
Avg Vol (3M)
$47.99K
Beta
-0.38
Div Yield
-
CYTH Company Profile
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
CYTH Performance
Peer Comparison
| Ticker | Company |
|---|---|
| ITCI | Intra-Cellular Therapies, Inc. |
| TKNO | Alpha Teknova, Inc. |
| AMRX | Amneal Pharmaceuticals, Inc. |
| AQST | Aquestive Therapeutics, Inc. |
| LFCR | Lifecore Biomedical, Inc. |
| PAHC | Phibro Animal Health Corporation |
| GHSI | Guardion Health Sciences, Inc. |
| IRWD | Ironwood Pharmaceuticals, Inc. |
| SSIC | Silver Spike Investment Corp. |
| ASRT | Assertio Holdings, Inc. |
| PTPI | Petros Pharmaceuticals, Inc. |
| ACRX | Talphera, Inc. |
| LSDI | Lucy Scientific Discovery Inc. |
| AGRX | Agile Therapeutics, Inc. |
| EGRX | Eagle Pharmaceuticals, Inc. |